Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Sponsor: GlaxoSmithKline
Summary
This study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.
Official title: A Phase 3, Double-blind, Randomized, Placebo Controlled, 2-arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Injection in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (NEBULA-1)
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
1740
Start Date
2026-07-20
Completion Date
2033-08-22
Last Updated
2026-07-14
Healthy Volunteers
No
Interventions
Efimosfermin alfa
Efimosfermin alfa (subcutaneous injection) will be administered.
Placebo
Placebo (subcutaneous injection) will be administered.